Determine the necessary mass, volume, or concentration for preparing a solution.
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
≥98% for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -20°C Ships Ice chest + Ice pads Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 8 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Information
Berbamine Berbamine (BA), a traditional Chinese medicines extracted from Berberis amurensis (xiaoboan), is a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity and also an inhibitor of NF-κB . Berbamine (BA) induces apoptosis in human myeloma cells and inhibits the growth of cancer cells by targeting Ca²⁺/calmodulin-dependent protein kinase II (CaMKII) .
Targets
Bcr-Abl ; NF-κB ; CaMKII
| ALogP | 6.992 |
|---|---|
| hba_count | 5 |
| HBD数 | 1 |
| 回転可能な結合 | 3 |
| パブケム・シド | 504758259 |
|---|---|
| パブケム・シド・ウル | https://pubchem.ncbi.nlm.nih.gov/substance/504758259 |
| カノニカル・スマイル | CN1CCC2=CC(=C3C=C2C1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)CC6C7=C(O3)C(=C(C=C7CCN6C)OC)OC)O)OC |
| IUPAC Name | (1S,14R)-20,21,25-trimethoxy-15,30-dimethyl-7,23-dioxa-15,30-diazaheptacyclo[22.6.2.23,6.18,12.114,18.027,31.022,33]hexatriaconta-3(36),4,6(35),8,10,12(34),18,20,22(33),24,26,31-dodecaen-9-ol |
| InChIKey | DFOCUWZXJBAUSQ-URLMMPGGSA-N |
| INCHI | 1S/C37H40N2O6/c1-38-14-12-24-19-32(41-3)33-21-27(24)28(38)16-22-6-9-26(10-7-22)44-31-18-23(8-11-30(31)40)17-29-35-25(13-15-39(29)2)20-34(42-4)36(43-5)37(35)45-33/h6-11,18-21,28-29,40H,12-17H2,1-5H3/t28-,29+/m0/s1 |
| 異性体SMILES | CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)C[C@@H]6C7=C(O3)C(=C(C=C7CCN6C)OC)OC)O)OC |
| 分子量 | 608.72 |
| Reaxy-Rn | 78902 |
| Reaxys-RN_link_address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=78902&ln= |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →Taxonomy Tree
| Kingdom | Organic compounds |
|---|---|
| Superclass | Lignans, neolignans and related compounds |
| 分類 | Not available |
| Subclass | Not available |
| Intermediate Tree Nodes | Not available |
| Direct Parent | Lignans, neolignans and related compounds |
| Alternative Parents | Diarylethers Tetrahydroisoquinolines Anisoles Aralkylamines Alkyl aryl ethers 1-hydroxy-2-unsubstituted benzenoids Trialkylamines Oxacyclic compounds Azacyclic compounds Organopnictogen compounds Hydrocarbon derivatives |
| Molecular Framework | Aromatic heteropolycyclic compounds |
| Substituents | Oxyneolignan skeleton - Diaryl ether - Tetrahydroisoquinoline - Anisole - Alkyl aryl ether - 1-hydroxy-2-unsubstituted benzenoid - Aralkylamine - Benzenoid - Tertiary amine - Tertiary aliphatic amine - Ether - Oxacycle - Azacycle - Organoheterocyclic compound - Organonitrogen compound - Hydrocarbon derivative - Organic nitrogen compound - Organopnictogen compound - Organooxygen compound - Amine - Organic oxygen compound - Aromatic heteropolycyclic compound |
| 説明 | This compound belongs to the class of organic compounds known as lignans, neolignans and related compounds. These are plant products of low molecular weight formed primarily from oxidative coupling of two p-propylphenol moieties. They can also be described as micromolecules with two phenylpropanoid units coupled together. They can be attached in various manners, like C5-C5', C8-C8'. Most known natural lignans are oxidized at C9 and C9´ and, based upon the way in which oxygen is incorporated into the skeleton and on the cyclization patterns, a wide range of lignans of very different structural types can be formed. |
| External Descriptors | Isoquinoline alkaloids |
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | 日付 | 商品 |
|---|---|---|---|
| Certificate of Analysis | Aug 31, 2026 | B414342 | |
| Certificate of Analysis | Aug 31, 2026 | B414342 | |
| Certificate of Analysis | Aug 31, 2026 | B414342 | |
| Certificate of Analysis | Mar 13, 2026 | B414342 | |
| Certificate of Analysis | Oct 30, 2025 | B414342 | |
| Certificate of Analysis | Oct 30, 2025 | B414342 | |
| Certificate of Analysis | Oct 30, 2025 | B414342 | |
| Certificate of Analysis | Oct 30, 2025 | B414342 | |
| Certificate of Analysis | Sep 29, 2022 | B414342 | |
| Certificate of Analysis | Sep 29, 2022 | B414342 |
| 溶解度 | Solubility (25°C) In vitro DMSO: 100 mg/mL (164.27 mM); |
|---|---|
| DMSO(mg / mL) 最大溶解度 | 100 |
| DMSO(mM) 最大溶解度 | 164.278252532801 |
| 分子量 | 608.700 g/mol |
| XLogP3 | 6.100 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 3 |
| Exact Mass | 608.289 Da |
| Monoisotopic Mass | 608.289 Da |
| Topological Polar Surface Area | 72.900 Ų |
| Heavy Atom Count | 45 |
| Formal Charge | 0 |
| Complexity | 963.000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| The total count of all stereochemical bonds | 0 |
| Covalently-Bonded Unit Count | 1 |
| 1. Pan Wu, Yaru Fang, Kezhou Chen, Mi Wu, Wenchang Zhang, Shiyu Wang, Dongwen Liu, Junqing Gao, Huaiguo Li, Jianhua Lv, Yan Zhao. (2023) Study of double network hydrogels based on sodium methacrylate alginate and carboxymethyl chitosan. EUROPEAN POLYMER JOURNAL, [PMID:] [10.1016/j.eurpolymj.2023.112137] |
| 2. Heng Zhang, Yizheng Zhou, Hanmo Yang, Xinyi Tao, Yinping Chen, Fuqiang Dong, Yi Sun. (2025) In vitro interactions of berbamine hydrochloride and azoles against Aspergillus fumigatus. Microbiology Spectrum, [PMID:40162754] [10.1128/spectrum.03184-24] |
| 3. Hui Wang, Mingyu Wang, Jinku Zhang, Di Wu, Zhezhe Qi, Xinbei Dong, Xing Zhang, Hongyuan Yan, Yehong Han. (2025) Green synthesis of a urea–melamine–hexamethylenetetramine resin for efficient extraction and determination of berberine hydrochloride in Pudilan antiphlogistic oral liquid. JOURNAL OF CHROMATOGRAPHY A, [PMID:40652811] [10.1016/j.chroma.2025.466196] |
| 4. Xinru Wang, Jie Zhang, Jinyu Shan, Dong Yang, Jie Yang, Guangming Tian, Yunzhi Dang, Jianhua Ma. (2025) Polypyrrole-Modified Triple-Responsive Hydrogel Dressing Based on Bacterial Cellulose and Quaternary Ammonium Chitosan and Its Synergistic Antibacterial Mechanism. ACS Applied Materials & Interfaces, [PMID:40890037] [10.1021/acsami.5c12061] |
| 5. Xinru Wang, Jinyu Shan, Jie Zhang, Dong Yang, Guangming Tian, Yunzhi Dang, Jianhua Ma. (2025) Synergistic thermoresponsive and photothermal antimicrobial dressing based on bacterial cellulose with surface-grafted PNIPAM and PDA-coated silver nanoparticles for chronic wound treatment. COLLOIDS AND SURFACES A-PHYSICOCHEMICAL AND ENGINEERING ASPECTS, [PMID:] [10.1016/j.colsurfa.2025.138357] |
| 6. Mengyuan Li, Jiaming Ge, Jingwen Yao, Yuanhao Zhang, Lin Ma, Zheng Li, Xiangli Han, Ming Liu, Fei Tian, Jing Zhao. (2025) Multifunctional nanoplatform based on polyethylene glycol-folic acid modified UiO-66 (Zr) as drug delivery platform for enhanced therapy of cancer. Biofabrication, 17 (3): (035012). [PMID:40378851] [10.1088/1758-5090/add9d2] |
| 7. Xue-Na Li, Ya-Ping Lin, Xi-Xi Ma, Yue-Fei Fang, Hui Wang, Chun-Hui Cui, Chen Zhang, Jin-You Piao, Jee-Heon Jeong, Xian Wu Cheng, Lei Xing, Hu-Lin Jiang. (2025) Pulmonary-Targeted Nanoparticles Interrupt the Malignant Mechanical and Biochemical Signaling Crosstalk for Idiopathic Pulmonary Fibrosis Therapy. Advanced Science, [PMID:41246879] [10.1002/advs.202512658] |
| 8. Chunling Yuan, Li Zheng, Hongxia Hu, Xue Cheng, Peng Liu. (2026) Berbamine improves behavioral impairments in Huntington's disease mice models through inhibiting Src/AKT1/NFκB signaling pathway and attenuating Src-mediated mitophagy suppression. INTERNATIONAL IMMUNOPHARMACOLOGY, [PMID:42407179] [10.1016/j.intimp.2026.117092] |